Ovarian tumor cell (None)

Ovarian tumor cells are the malignant cellular components of ovarian neoplasms, characterized by high histological heterogeneity and the capacity for aggressive peritoneal dissemination (NIH, 2024). While the term refers to a cellular entity rather than a single molecular target, these cells express several clinically relevant molecules such as Folate Receptor Alpha (FRα), MUC16 (CA-125), and DNA repair enzymes like PARP, which serve as the actual therapeutic targets (PubMed, 2022). Ovarian tumor cells often exhibit genomic instability, with frequent mutations in TP53 and BRCA1/2 that render them sensitive to specific agents like platinum-based chemotherapies and PARP inhibitors (Molecular Cancer Therapeutics, 2018). Modern therapies utilize monoclonal antibodies and antibody-drug conjugates to specifically identify surface antigens on these cells and deliver cytotoxic payloads or disrupt growth-signaling pathways (NIH, 2025). Despite treatment advances, the ability of these cells to undergo metabolic adaptation and develop chemoresistance remains a significant therapeutic challenge in managing recurrent disease (PMC, 2021).

Other names

Ovarian cancer cellMalignant ovarian cellOvarian carcinoma cellEpithelial ovarian cancer cellOvarian neoplasm cell

Targeting of ovarian tumor cells is achieved through multiple molecular strategies, including DNA alkylation and cross-linking to induce apoptosis, stabilization of microtubules to arrest mitosis, inhibition of poly(ADP-ribose) polymerase (PARP) to prevent DNA single-strand break repair in BRCA-deficient cells, and blockade of vascular endothelial growth factor (VEGF) to inhibit tumor-associated angiogenesis.